Bristol-Myers Squibb Research Institute, 2-9-3 Shimo-meguro, Meguro-ku, Tokyo 153, Japan (Received for publication October 8, 1992) The biosynthetic pathway of the pradimicin-benanomicin family of antibiotics was investigated by using sinefungin and blocked mutants derived from Actinomaduraverrucosospora subsp. neohibisca E-40 (a high pradimicin producer) or Actinomadura sp. AB 1236 (a benanomicin producer). Addition of sinefungin to strain E-40, pradimicin A aglycone-producing mutant or strain AB1236inhibited the formation of ll-O-demethyl-7-methoxypradinone II (lldM-7M-PN II), resulting in the accumulation of 1 1-O-demethylpradimicinone II and pradimicinone II. By feeding pradimicin A aglycone and its analogs to mutants blocked early in pradimicin or benanomicin biosynthesis, the following results were obtained: 1 1-O-demethylpradinone II, 1 ldM-7M-PNII, 1 1-0-demethylpradinone I, ll-0-demethylpradimicinone I and pradimicinone I were converted to pradimicin A or benanomicin A; the remaining 6 aglycone analogs were not incorporated into the antibiotics. Pradimicin B, dexylosylpradimicin C and dexylosylbenanomicin A were converted to pradimicin A, pradimicin C and benanomicin A, respectively. A biosynthetic pathway for the antibiotics is proposed.
The pradimicins and benanomicins are new antifungal antibiotics of dihydrobenzo [a] naphthacenequinone family produced by strains belonging to the single genus Actinomadura1 "^. Both antibiotics have a dihydrobenzo[a]naphthacenequinone chromophore with a methoxyl group at C-l l. Biosynthetic studies of benanomicins revealed that this methoxyl group was introduced from a methionine-derived methyl group6). Sinefungin, an analog of S-adenosyl methionine (SAM) is a potent and specific inhibitor of 0-methyltransferase and other methyltransferase7~1 1}. Consequently, addition of sinefungin to the above 2 strains and 6 mutants which accumulate analogs of pradimicin A aglycone is worth examining for understanding of these antibiotics biosynthesis. In the mean time, we have reported12>13) that some of
I (l ldM-PN I), pradinone I (PN I), 1 1-0-demethylpradimicinone I (l ldM-PMN I) and pradimicinone I (PMN I) accumulated by 3 mutants of classes IV, V and VI would be true biosynthetic intermediates of pradimicins, whereas l l-O-demethyl-6-deoxypradinone I (HdM-6dO-PNI), 1 1-0-demethylpradimicinone II (1 ldM-PMNII), pradimicinone II (PMN II) and 7-methoxypradimicinone II (7M-PMNII) might be shunt metabolites associated with the pradimicins biosynthesis. To prove this, we investigated the bioconversion of these compoundsusing growing cultures of both pradimicin-and benanomicin-nonproducing mutants (blocked mutants). Fromthe above information, we propose the subunit assembly in the biosynthetic pathway for both pradimicins and benanomicins as summarized in Fig. 1 Actinomaduraverrucosospora subsp. neohibisca E-40 and its blocked mutants used in this report have been described in preceding papers12 '14) . Actinomadura sp. AB1236which produces benanomicins has been described15).
Media
TP medium consisting of glucose 3%, defatted soybean meal (Esusan mi-to, Ajinomoto Co., Ltd.) 3% and CaCO30.3% was used for bioconversion experiments. Seed medium (BS) was prepared with soluble starch 1% and defatted soybean meal 3%. Production medium (BP) was prepared with glucose 2%, Pharmamedia (Traders Protein) 1% and KH2PO40.1%. The BS and BP media were used for the production of benanomicins.
Isolation of Converter Strain from Strain AB1236 Mutagenesis of the strain AB1236was carried out as previously described12). Colonies which produce no diffusible pigment were fermented in the BP mediumto confirm a lack of the production of benanomicins. Benanomicin-nonproducing mutants thus obtained were inoculated as a patch on a GBS agar medium12) supplemented with lldM-PN II (250y/ml) and incubated at 30°C for 7 days. Mutant strain B-6 which formed red pigment around the colony was selected as a converter strain.
Fermentation
A 5%inoculum of strain E-40 or its mutants grown in V-15 mediumwas transferred to 100ml of FR-1 8 medium supplemented with different concentration of sinefungin (Calbiochem Corporation) in a 500-ml flask and was incubated at 28°C for 7 days. 5% seed of strain AB1236 grown in the BS medium was transferred to 100ml BP medium supplemented with sinefungin in a 500-ml flask and incubated at 28°C for 7 days. Metabolites in the broth supernatant were determined by TLCand HPLC12) and quantitated by absorbance at 460 nm12). Bioconversion 5% inoculum of strain JN-213 (or strain B-6) grown in V-15 medium (or BS medium) was transferred to 100ml ofTP medium (or BP medium) in a 500-ml flask and incubated at 28°C for 48 hours. Substrate was added to 4ml of a 48-hour growing culture prepared and incubated at 28°C and 200 rpm on a shaker. Products in the supernatant were analysed by TLCand HPLC12).
Results

Effect of Sinefungin on the Production of Pradimicins and Benanomicins
Normally, A. verrucosospora subsp. neohibisca E-40 and A. sp. AB1236produce pradimicins A and C (PRM A and C) and benanomicins (BNM A and B; BNMB is identical to PRMC), respectively, as major components together with several minor components. As both antibiotics have a methoxyl group at C-ll on the aglycone moiety, the effect of sinefungin was investigated on the production of both antibiotics by strains E-40 and AB1236. As shown in Table 1 , addition of sinefungin (0.0228 him) inhibits the formation of pradimicins and causes the accumulation of two aglycone analogs, 1 1dM-PMN II and PMNII. lldM-PMN II and PMNII were isolated and identified by direct comparison. In the case of benanomicins (Table 2) , sinefungin (0.1 14mM)results in a concomitant accumulation of 1 1dM-PMNII and PMNII together with two new components which are thought to be the 7-hydroxyl analogs of BNM A and PRMC (7OH-BNMA and 7OH-PRMC). We reported earlier that 10 analogs of pradimicin A aglycone including three 7-methoxyl compounds (lldM-7M-PN II, lldM-7M-PMN II and 7M-PMN § i 3 ft Table 1 . Effect of sinefungin on the production ofpradimicins by strain E-40. MAR. 1993 Metabolite (we/ml) II) were produced by 6 mutant strains12 '13) . Therefore, we also examined the effect of sinefungin on the formation of these compounds by strains JN-219, JN-47, JNU-46, JN-58, JN-59 and JN-207. Expectedly, sinefungin (0.00228 him) completely blocks the formation of 7-methoxyl compounds (l ldM-7M-PN II, lldM-7M-PMN II and 7M-PMNII), ll-methoxyl compounds (PN I and PMNI except for PMNII), lldM-PN I and lldM-PMN I and causes the accumulation of lldM-PMN II and PMNII (Table 3) . The formation of HdM-6dO-PNI and 7OH-PRMA produced by strains JN-58 and JN-207 was not I. This would suggest that 0-methylation at the C-7 position followed by demethoxylation is required for the biosynthetic process from lldM-PN II to lldM-PN I.
Bioconversion by Pradimicin-and Benanomicin-nonproducing Mutants
From the results with sinefungin and cosynthesis, it appeared that one or more of the accumulated compound i.e. lldM-PN II, lldM-7M-PN II, lldM-PN I, PN I, lldM-PMN I and PMN I would be true biosynthetic intermediates of pradimicin biosynthesis. Subsequently, they were fed to converter strains. Preliminary experiments showed that these aglycone analogs, except for PN I, were slowly incorporated into pradimicins, though the yields of bioconverted products were quite variable depending on the culture age of the mutants used. For example, when exogenously added lldM-PN II was incubated with the strain JN-213, PRMA and B appeared within 4 hours and disappearance of the substrate occurred after 24 hours (Fig. 2) . In contrast, attempts to convert lldM-PMN II, lldM-7M-PMN II, PMNII, 7M-PMN II and HdM-6dO-PNI to PRMA failed (data not shown). Concerning the biosynthesis of PN I and 1 ldM-6dO-PN I, PN I may be biosynthesized from 1 ldM-PN I as a shunt metabolite and the biosynthetic pathway to HdM-6dO-PNI remains to be resolved. Table 4 presents typical results which demonstrate the bioconversion of possible biosynthetic intermediates by the converter strain JN-213. After 17 hours, 1 ldM-PN II is converted to PRMB (ll.2%) and PRMA (71.2%) as well as trace amounts of 1ldM-PN I, 1ldM-PMN I and PMNI. 1ldM-7M-PN II is similarly converted to lldM-PMN I (6.4%), PRM B (7.3%) and PRM A (25.1%). lldM-PN I is also converted to 1ldM-PMN I (14.2%) and PRM B (14.4%) and PRM A (61.4%). 1ldM-PMN I is converted to PRM A (9.7%), and PMN I is converted to PRM B (3.4%), PRM A (3.7%) and 1ldM-PMN I (9.2%), among which the accumulation of 1 ldM-PMN I may be caused by degradation. These results suggest that pradimicins are biosynthesized from 1 ldM-PN II via 1 ldM-7M-PM II, 1 ldM-PN I, 1ldM-PMN I and PMN I.
Bioconversion of lldM-PN II, lldM-7M-PN II, lldM-PN I, lldM-PMN I and PMN I
To clarify this, the effect of sinefungin on the byconversion of l ldM-PN II, lldM-7M-PN II and lldM-PN I by strain JN-213 was also investigated. As shown in cf. Footnote of Table 4 , except below. Culture medium (BP): Glucose 2%, Pharmamedia 1% and KH2PO40.1%. Method: The substrate (0.5~0.8/miol) was added to 4ml of 48-hour growing cultures of strain B-6. After incubation for additional 72 hours at 28°C, products were determined by HPLCand TLC.
after addition of the substrate. Interestingly, in the presence of sinefungin (0.0018mM), l ldM-7M-PN II is converted into PRM A (28%), and lldM-PN I is incorporated into PRM A (36.3%) via lldM-PMN I (36.7%). PMNI was also incorporated into PRMA (data not shown).
Since the aglycone of benanomicins is identical with PMNI4), it is assumed that benanomicins would also be biosynthesized from lldM-PN II via lldM-7M-PN II, lldM-PN I, lldM-PMN I and PMNI. These 5 compounds were examined to determine whether or not they were incorporated into benanomicins by strain B-6. Strain B-6 is a mutant blocked in benanomicin production and acts as a converter strain (see Materials and Methods). As shown in Table 6 , the antibiotics produced are benanomicins. The result is quite identical to those observed on the formation of pradimicins. From the information obtained above, a biosynthetic sequence, namely l ldM-PN II->lldM-7M-PN II->lldM-PN I-åºlldM-PMN I-+PMN I-+PRM A or BNMA, was determined.
Since lldM-PMN II, lldM-7M-PMN II, PMN II and 7M-PMN II failed to be converted to PRM A or BNMA and 1ldM-PN II is converted to 1ldM-PMN II and PMN II in the presence of sinefungin, a shunt metabolic pathway is proposed as follows:
Bioconversion of the Aglycone Glycosides Tables 7 and 8 whereas dX-PRM C and dexylosylbenanomicin A (dX-BNM A) are incorporated into PRM C (19.5% and 15.3%) and BNMA (40.4% and 51.7%), respectively (Table 8 ). These results indicate that PRMB, dX-PRMC and dX-BNMA are precursors for PRMA, PRMC and BNMA, respectively. In conclusion, the biosynthetic pathway of pradimicin A and benanomicin A is as described in Fig. 1 . cf. Footnote of Table 4 . respectively. The blocked site of mutant JN-58 must be on the pathway which is associated with 7-O-methylation. The blocked site of mutant JN-59 seems to be located on the steps for 5-0-glycosidation and/or demethoxylation at the C-7 position.
Discussion
Pradimicins and benanomicins have a methoxyl group at C-ll on the aglycone moiety, which has been shown to be derived from the methyl of methionine6). The present findings with sinefungin suggest that A. verrucosospora subsp. neohibisca possesses two distinct methyltransferases, which catalyze methylation of the aglycone moiety at C-7 or C-l 1. 7-O-Methylation would occur prior to 1 1-O-methylation followed by 5-0-glycosidation in the biosynthesis of the antibiotics.
These methoxyl groups arise via an SAM-dependentmethyltransferase. It is important to note than the 0-methylation at C-7 position is crucial in the early steps of the biosynthetic pathway, since blocking the 0-methylation resulted in the formation of shunt products. Antibiotic-blocked mutants have provided essential information that has led to understanding of antibiotic biosynthesis. Thus, it is of interest to point out that in Step 1 (formation of lldM-PN II), lldM-PN II isolated from mutant strain JN-219 appears to be biosynthesized from a dodecaketide precursor6'16) and is considered to be the initial intermediate. In Steps 2 and 3 (formation of l ldM-7M-PN II and 1 ldM-PN I), the pathway, represented by strain JN-219, is O-methylation at C-7 position followed by demethoxylation.
lldM-7M-PN II undergoes an unusual demethoxylation process leading to the formation of l ldM-PNI. The precise mechanism by which the methoxyl is lost and the conformation at C-5/C-6 is changed13) remains to be resolved. In
Step 4 (formation of lldM-PMN I), the reaction,
represented by strain JN-47, is D-alanylation at the C-15 position of lldM-PN I. The D-alanine may be biosynthesized from L-alanine by alanine racemase16). In
Step 5 (formation of PMNI),.the reaction, represented by strain JNU-46, is ll-O-methylation of lldM-PMNI. This methoxyl group may also be derived from the methyl of methionine. In Steps 6 and 7 (formation of dexylosyl analogs and pradimicins or benanomicins), these steps are 5-O-glycosidation of PMNI followed by C-3'-glycosidation of dexylosyl analogs of the antibiotics. The precise pathway of dexylosyl analog formation cannot be determined until the blocked mutants corresponding to each of them are isolated.
